Search
Luteci (177Lu) oxodotreotida per al tractament de tumors neuroendocrins gastroenteropancreàtics positius al receptor de somatostatina, ben diferenciats, progressius i irresecables o metastàtics
(2020-07-07)
Neuroendocrine tumors (TNEs) are defined as those neoplasms with a predominantly neuroendocrine cell differentiation, which can arise in most organs, although most are of gastrointestinal or pancreatic origin (≈65%). The ...
Trastuzumab per al tractament del càncer gàstric o d'unió gastroesofàgica metàstasic HER2+: informe d'avaluació de resultats
(2018)
Trastuzumab is a humanized monoclonal antibody against human epidermal growth factor (HER2) receptor 2, which in 2010 was approved by the European Agency of the
Medication (EMA) for the treatment of gastric cancer or ...
Tractament del CPNM metastàtic EFGR positiu amb inhibidors d’ITK en primera línia: informe d'avaluació de resultats
(2021)
Lung cancer (LC) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of new cases of LC for 2019 was 29,503 cases. LC remains the leading cause of cancer death in Spain in both ...
Durvalumab per al tractament del càncer de pulmó no microcític estadi III irresecable
(2020-03-25)
Non-microcytic lung cancer (CPNM) in stage III consists of a heterogeneous population with two subsets: stage IIIA and IIIB. Most patients with stage IIIA / B have an inoperable (non-resectable) disease. Only a third of ...
Tractament del CPNM metastàtic en primera i segona línia amb immunoteràpia: informe d'avaluació de resultats
(2021)
Lung cancer (LC) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of LC for 2019 was 29,503 new cases. LC remains the leading cause of cancer death in Spain in both sexes, with ...
Axicabtagen ciloleucel i tisagenlecleucel per al tractament del limfoma B de cèl·lules grans
(2019-03-21)
Axicabtagen ciloleucel and tisagenlecleucel are two gene therapies that contain
T-lymphocytes of the patient previously manipulated so they express themselves
membrane, chimeric antigenic receptor or CAR. This receiver ...
Sorafenib i lenvatinib per al tractament en primera línia del carcinoma hepatocel·lular (CHC)
(2020-07-29)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, the fifth most common cancer in men and the seventh in women, and is associated with high mortality, which is the third leading cause of cancer death. ...